Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

Rotech Healthcare prices $230 million Senior Secured Notes offering

Rotech Healthcare Inc. announced today the pricing of its offering of $230 million in aggregate principal amount of Senior Secured Notes due 2015. The notes will be sold to investors at a price of 97.189% of the principal amount thereof and will bear a coupon rate equal to 10 ¾ % per annum. The offering is expected to close on October 6, 2010.

30 Sep 2010

Rotech Healthcare offers $225 million in Senior Secured Notes due 2015

Rotech Healthcare Inc. announced today that the company intends to offer, subject to market and other conditions, $225 million in aggregate principal amount of Senior Secured Notes due 2015.

27 Sep 2010

UC San Diego receives grant to study hypoxia susceptibility

Gabriel G. Haddad, MD, chair of the Department of Pediatrics at the University of California, San Diego School of Medicine and Physician-in-Chief at Rady Children's Hospital-San Diego has received a $10 million grant from the National Institute of Health's Heart, Lung and Blood Institute.

24 Sep 2010

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera's aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea. The target population for ImThera's neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure.

22 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

A study in the Sept. 1 issue of the journal SLEEP found an elevated risk of death in men with a complaint of chronic insomnia and an objectively measured short sleep duration. The results suggest that public health policy should emphasize the diagnosis and appropriate treatment of chronic insomnia.

2 Sep 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

ResMed revenue increases 16% to $291.6 million for quarter ended June 30, 2010

ResMed Inc. today announced record revenue and income for the quarter ended June 30, 2010, and a two-for-one stock split.

From ResMed Corp 6 Aug 2010

Rotech Healthcare second-quarter adjusted EBITDA increases to $29.2 million

Rotech Healthcare Inc. today announced financial results for the three and six months ended June 30, 2010.

5 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Graymark Healthcare adds two new sleep centers in Texas, Nebraska

Graymark Healthcare announced that it has added two new sleep centers in Texas and Nebraska with the signing of agreements to provide on-site services to Goodall-Witcher Medical Center in Central Texas and Henderson Community Hospital in Nebraska. These agreements continue to execute on Graymark's strategy to expand the availability of sleep medicine in rural communities that otherwise might not have access to comprehensive sleep care.

30 Jul 2010

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.

16 Jul 2010

Rotech Healthcare accepts 17 CMS contracts in Round 1 Rebid of Medicare Competitive Bidding Program

Rotech Healthcare Inc. today announced that it has accepted 17 contracts awarded by the Centers for Medicare & Medicaid Services in the Round 1 Rebid of the national Medicare Competitive Bidding Program. The Round 1 Rebid included nine metropolitan statistical areas. Only contracted suppliers can service Medicare patients for the competitively-bid product categories in these locations, with a few exceptions. The new contracts awarded in Round 1 have a three-year term and are scheduled to take effect on January 1, 2011.

13 Jul 2010

Sleep apnea may increase risk of heart disease and death by 68%: Study

Obstructive sleep apnea (OSA) that leads to snoring and is actually caused by frequent collapse of the airway during sleep makes it difficult for sufferers to breathe for periods lasting as long as 10 seconds. Severe sufferers may have 30 such apnoeic or breathless episodes per hour that can severely disrupt sleep.

13 Jul 2010

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patients who were denied bariatric surgery for insurance reasons developed a slew of new obesity-related diseases and conditions within three years of follow-up, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

24 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

VIVUS to present data on Qnexa at ENDO meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the Endocrine Society's 92nd Annual Meeting and Expo in San Diego, California. Timothy Garvey, M.D., professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation at the Clinical Trials Symposium on Saturday, June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities."

16 Jun 2010